Based on these available clinical data, and the reduction in plasma NFL concentration provides clinical benefits in tofersen-treated patients with SOD1-ALS, tofersen has been approved by FDA in April 2023. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.